Inovio Pharmaceuticals - Articles and news items

Approval for first-in-human Zika vaccine trial to go ahead

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Inovio and GeneOne Life Science have received approval to initiate a Phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700)…

Inovio’s Ebola vaccine generates robust immune responses in humans

Industry news / 30 March 2016 / Victoria White

Inovio’s Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its Phase I study of 75 healthy subjects…

Patient recruitment starts for MERS vaccine trial

Industry news / 28 January 2016 / Victoria White

Inovio and GeneOne Life Science are co-developing Inovio’s MERS vaccine (GLS-5300) in partnership with the Walter Reed Army Institute of Research…

INO-3112 shows robust responses in head and neck cancer

Industry news / 6 November 2015 / Victoria White

Immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18…

Successful Phase 2b trial results of HPV immunotherapy VGX-3100 announced

Industry news / 17 September 2015 / Victoria White

VGX-3100 is the first therapy to demonstrate that activated killer T cells induced in the body have the power to clear neoplastic lesions as well as the virus…

First patient dosed in Phase I trial of universal HIV vaccine Pennvax-GP

Industry news / 8 September 2015 / Victoria White

The trial will measure immune responses following administration of Pennvax-GP in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12)…

Medimmune to develop DNA-based immunotherapies for cancer and infectious diseases

Medimmune and Inovio Pharmaceuticals agree to DNA-based immunotherapy collaboration

Industry news / 11 August 2015 / Katie Sadler, Digital Content Producer, European Pharmaceutical Review

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.

Inovio initiates Phase I trial of its Ebola DNA immunotherapy

Industry news / 12 May 2015 / Victoria White

Inovio Pharmaceuticals has initiated a Phase I trial to evaluate safety, tolerability and immune responses of its Ebola DNA immunotherapy…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...